Effect of Desmopressin on Platelet Function in CKD Patients on Antiplatelet Drug

University of Ulsan

Status and phase: Completed; Phase 1

Conditions: Dyspnea; Tachycardia; Bleeding

Treatments: Drug: Desmopressin administration

Study type: Interventional

Funder types: Other

Identifiers

NCT01841515

NCT00134031

Details and patient eligibility

About

Prolonged Collagen/Epinephrine - closure time (CEPI-CT) indicates platelet dysfunction in CKD patients taking antiplatelet agent. The synthetic vasopressin derivative, Desmopressin (DDAVP) shortens the prolonged bleeding time and improves platelet dysfunction measured by in vitro closure time: CEPI-CT in uremic patients. Desmopressin also antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors, clopidogrel and aspirin. The investigators designed a prospective study to evaluate the effect of desmopressin on platelet function, as measured by in vitro collagen/epinephrine - closure time, in uremic patients who were taking antiplatelet drugs.

Enrollment: 25 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• adult uremic patients with one or more antiplatelet medication,
• prolonged collagen/epinephrine (CEPI) closure time,
• need for emergent hemodialysis and
• subsequent catheter insertion

Exclusion criteria

• acute coronary syndrome,
• hemophilia, and nephrogenic diabetes insipidus,
• allergy against desmopressin

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

25 participants in 1 patient group

Desmopressin

Experimental group

Description:

Twenty five patients with chronic kidney disease and who were taking antiplatelet agents and needed an emergent catheter insertion for hemodialysis

Treatment:

Drug: Desmopressin administration